Series C · Biotech
Adcendo: Series C
Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment
Funding history
Series C · This round$75M
Loading rounds…
Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment